PUNE, India, November 21, 2016 /PRNewswire/ -- ReportsnReports.com adds "Tuberculosis - Pipeline Review, H2 2016" to its store providing comprehensive information on the therapeutics under development for Tuberculosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Complete report on H2 2016 pipeline review of Tuberculosis with 108 market data tables and 17 figures, spread across 393 pages is available at http://www.reportsnreports.com/reports/755901-tuberculosis-pipeline-review-h2-2016.html. Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. Companies discussed in this Tuberculosis Pipeline Review, H2 2016 report include Abera Bioscience AB, Akthelia Pharmaceuticals Limited, Alvogen Korea Co., Ltd., Anacor Pharmaceuticals, Inc., Archivel Farma S.L., AstraZeneca Plc, Beech Tree Labs, Inc., BioDiem Ltd, BioLingus AG, Biomar Microbial Technologies, Bioversys AG, Celgene Corporation, Cellceutix Corporation, Chongqing Zhifei Biological Products Co., Ltd., Crestone, Inc., Dafra Pharma International Ltd., Daiichi Sankyo Company, Limited, Demuris Limited, Eisai Co., Ltd., Eli Lilly and Company, Ensol Biosciences Inc., EpiVax, Inc., FIT Biotech Oy, GangaGen Inc., GlaxoSmithKline Plc, Globeimmune, Inc., Hager Biosciences, LLC, Hsiri Therapeutics LLC, Imaxio SA, Immunitor, Inc., ImmunoBiology Limited, Inovio Pharmaceuticals, Inc., Johnson & Johnson, Lakewood-Amedex Inc, Lipotek Pty Ltd., Matinas BioPharma Holdings, Inc., Microbion Corporation, Microbiotix, Inc., NEARMEDIC PLUS, Ltd, Novartis AG, NovoBiotic Pharmaceuticals, LLC, Otsuka Holdings Co., Ltd., QureTech Bio AB, Recce Pty Ltd, Rodos BioTarget GmbH, Sanofi, Sanofi Pasteur SA, Sarepta Therapeutics, Inc., Sequella, Inc., Shionogi & Co., Ltd., Sphaera Pharma Pvt. Ltd., Spring Bank Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, TetraLogic Pharmaceuticals, TGV-Laboratories, Theravectys SA, Tomegavax, Inc., Transgene SA, TVAX Biomedical, Inc., Univalue Valorizacion, S.L., Vaccibody AS, Vakzine Projekt Management GmbH, Vaxil Bio Therapeutics Ltd. and Vichem Chemie Research Ltd. Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=755901. The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 7, 8, 61, 37 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 4, 5, 35 and 37 molecules, respectively.